Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Topical BAY1003803 in Healthy Volunteers
NCT02936492Phase 1Terminated
- Sponsor
- Bayer
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAY1003803 in psoriasis (3 arms), sponsored by Bayer. Primary endpoints: Cortisol serum levels for safety up to 2 weeks and Frequency and Nature of treatment-emergent adverse events up to 2 weeks. Started Oct 2016; status: terminated.
02
Drugs
BAY1003803
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02936492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936492.